Literature DB >> 15455477

Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.

.   

Abstract

This final rulemaking is issued by the Deputy Administrator of the Drug Enforcement Administration (DEA) to place alpha-methyltryptamine (AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) into Schedule I of the Controlled Substances Act (CSA). This action by the DEA Deputy Administrator is based on a scheduling recommendation by the Department of Health and Human Services (DHHS) and a DEA review indicating that AMT and 5-MeO-DIPT meet the criteria for placement in Schedule I of the CSA. This final rule will continue to impose the regulatory controls and criminal sanctions of Schedule I substances on the manufacture, distribution, and possession of AMT and 5-MeO-DIPT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455477

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  9 in total

1.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

2.  Alterations in body temperature, corticosterone, and behavior following the administration of 5-methoxy-diisopropyltryptamine ('foxy') to adult rats: a new drug of abuse.

Authors:  Michael T Williams; Nicole R Herring; Tori L Schaefer; Matthew R Skelton; Nicholas G Campbell; Jack W Lipton; Anne E McCrea; Charles V Vorhees
Journal:  Neuropsychopharmacology       Date:  2006-10-18       Impact factor: 7.853

3.  Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Pharmacol Rep       Date:  2016-02-05       Impact factor: 3.024

4.  Glucose and corticosterone changes in developing and adult rats following exposure to (+/-)-3,4-methylendioxymethamphetamine or 5-methoxydiisopropyltryptamine.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2009-09-06       Impact factor: 3.763

5.  Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Donald E Mager; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2013-02-07       Impact factor: 3.922

6.  Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents.

Authors:  William E Fantegrossi; Chad J Reissig; Elyse B Katz; Haley L Yarosh; Kenner C Rice; Jerrold C Winter
Journal:  Pharmacol Biochem Behav       Date:  2007-09-14       Impact factor: 3.533

7.  Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats.

Authors:  Matthew R Skelton; Tori L Schaefer; Nicole R Herring; Curtis E Grace; Charles V Vorhees; Michael T Williams
Journal:  Psychopharmacology (Berl)       Date:  2009-02-06       Impact factor: 4.530

8.  Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT1A receptor in the mouse striatum and prefrontal cortex.

Authors:  Yoko Hagino; Frank Scott Hall; George R Uhl; Ichiro Sora; Kazutaka Ikeda
Journal:  Neuropsychopharmacol Rep       Date:  2021-02-06

9.  Substance use and sexual behaviours of Japanese men who have sex with men: a nationwide internet survey conducted in Japan.

Authors:  Yasuharu Hidaka; Seiichi Ichikawa; Junko Koyano; Michiko Urao; Toshihiko Yasuo; Hirokazu Kimura; Masako Ono-Kihara; Masahiro Kihara
Journal:  BMC Public Health       Date:  2006-09-26       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.